Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals

Andrew M. Bellinger, Mousa Jafari, Tyler M. Grant, Shiyi Zhang, Hannah C. Slater, Edward A. Wenger, Stacy Mo, Young Ah Lucy Lee, Hormoz Mazdiyasni, Lawrence Kogan, Ross Barman, Cody Cleveland, Lucas Booth, Taylor Bensel, Daniel Minahan, Haley M. Hurowitz, Tammy Tai, Johanna P. Daily, Boris Nikolic, Lowell WoodPhilip A. Eckhoff, Robert Langer, Giovanni Traverso

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Efforts at elimination of scourges, such as malaria, are limited by the logistic challenges of reaching large rural populations and ensuring patient adherence to adequate pharmacologic treatment. We have developed an oral, ultra-long-acting capsule that dissolves in the stomach and deploys a star-shaped dosage form that releases drug while assuming a geometry that prevents passage through the pylorus yet allows passage of food, enabling prolonged gastric residence. This gastric-resident, drug delivery dosage form releases small-molecule drugs for days to weeks and potentially longer. Upon dissolution of the macrostructure, the components can safely pass through the gastrointestinal tract. Clinical, radiographic, and endoscopic evaluation of a swine largeanimal model that received these dosage forms showed no evidence of gastrointestinal obstruction or mucosal injury. We generated long-acting formulations for controlled release of ivermectin, a drug that targets malariatransmitting mosquitoes, in the gastric environment and incorporated these into our dosage form, which then delivered a sustained therapeutic dose of ivermectin for up to 14 days in our swine model. Further, by using mathematical models of malaria transmission that incorporate the lethal effect of ivermectin against malariatransmitting mosquitoes, we demonstrated that this system will boost the efficacy of mass drug administration toward malaria elimination goals. Encapsulated, gastric-resident dosage forms for ultra-long-acting drug delivery have the potential to revolutionize treatment options for malaria and other diseases that affect large populations around the globe for which treatment adherence is essential for efficacy.

Original languageEnglish (US)
JournalScience Translational Medicine
Volume8
Issue number365
DOIs
StatePublished - Nov 16 2016

Fingerprint

Dosage Forms
Malaria
Ivermectin
Stomach
Pharmaceutical Preparations
Culicidae
Swine
Gastrointestinal Agents
Pylorus
Rural Population
Patient Compliance
Capsules
Gastrointestinal Tract
Theoretical Models
Food
Wounds and Injuries
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bellinger, A. M., Jafari, M., Grant, T. M., Zhang, S., Slater, H. C., Wenger, E. A., ... Traverso, G. (2016). Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals. Science Translational Medicine, 8(365). https://doi.org/10.1126/scitranslmed.aag2374

Oral, ultra-long-lasting drug delivery : Application toward malaria elimination goals. / Bellinger, Andrew M.; Jafari, Mousa; Grant, Tyler M.; Zhang, Shiyi; Slater, Hannah C.; Wenger, Edward A.; Mo, Stacy; Lee, Young Ah Lucy; Mazdiyasni, Hormoz; Kogan, Lawrence; Barman, Ross; Cleveland, Cody; Booth, Lucas; Bensel, Taylor; Minahan, Daniel; Hurowitz, Haley M.; Tai, Tammy; Daily, Johanna P.; Nikolic, Boris; Wood, Lowell; Eckhoff, Philip A.; Langer, Robert; Traverso, Giovanni.

In: Science Translational Medicine, Vol. 8, No. 365, 16.11.2016.

Research output: Contribution to journalArticle

Bellinger, AM, Jafari, M, Grant, TM, Zhang, S, Slater, HC, Wenger, EA, Mo, S, Lee, YAL, Mazdiyasni, H, Kogan, L, Barman, R, Cleveland, C, Booth, L, Bensel, T, Minahan, D, Hurowitz, HM, Tai, T, Daily, JP, Nikolic, B, Wood, L, Eckhoff, PA, Langer, R & Traverso, G 2016, 'Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals', Science Translational Medicine, vol. 8, no. 365. https://doi.org/10.1126/scitranslmed.aag2374
Bellinger, Andrew M. ; Jafari, Mousa ; Grant, Tyler M. ; Zhang, Shiyi ; Slater, Hannah C. ; Wenger, Edward A. ; Mo, Stacy ; Lee, Young Ah Lucy ; Mazdiyasni, Hormoz ; Kogan, Lawrence ; Barman, Ross ; Cleveland, Cody ; Booth, Lucas ; Bensel, Taylor ; Minahan, Daniel ; Hurowitz, Haley M. ; Tai, Tammy ; Daily, Johanna P. ; Nikolic, Boris ; Wood, Lowell ; Eckhoff, Philip A. ; Langer, Robert ; Traverso, Giovanni. / Oral, ultra-long-lasting drug delivery : Application toward malaria elimination goals. In: Science Translational Medicine. 2016 ; Vol. 8, No. 365.
@article{51772f1c15294994aa22529fd4a8c33c,
title = "Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals",
abstract = "Efforts at elimination of scourges, such as malaria, are limited by the logistic challenges of reaching large rural populations and ensuring patient adherence to adequate pharmacologic treatment. We have developed an oral, ultra-long-acting capsule that dissolves in the stomach and deploys a star-shaped dosage form that releases drug while assuming a geometry that prevents passage through the pylorus yet allows passage of food, enabling prolonged gastric residence. This gastric-resident, drug delivery dosage form releases small-molecule drugs for days to weeks and potentially longer. Upon dissolution of the macrostructure, the components can safely pass through the gastrointestinal tract. Clinical, radiographic, and endoscopic evaluation of a swine largeanimal model that received these dosage forms showed no evidence of gastrointestinal obstruction or mucosal injury. We generated long-acting formulations for controlled release of ivermectin, a drug that targets malariatransmitting mosquitoes, in the gastric environment and incorporated these into our dosage form, which then delivered a sustained therapeutic dose of ivermectin for up to 14 days in our swine model. Further, by using mathematical models of malaria transmission that incorporate the lethal effect of ivermectin against malariatransmitting mosquitoes, we demonstrated that this system will boost the efficacy of mass drug administration toward malaria elimination goals. Encapsulated, gastric-resident dosage forms for ultra-long-acting drug delivery have the potential to revolutionize treatment options for malaria and other diseases that affect large populations around the globe for which treatment adherence is essential for efficacy.",
author = "Bellinger, {Andrew M.} and Mousa Jafari and Grant, {Tyler M.} and Shiyi Zhang and Slater, {Hannah C.} and Wenger, {Edward A.} and Stacy Mo and Lee, {Young Ah Lucy} and Hormoz Mazdiyasni and Lawrence Kogan and Ross Barman and Cody Cleveland and Lucas Booth and Taylor Bensel and Daniel Minahan and Hurowitz, {Haley M.} and Tammy Tai and Daily, {Johanna P.} and Boris Nikolic and Lowell Wood and Eckhoff, {Philip A.} and Robert Langer and Giovanni Traverso",
year = "2016",
month = "11",
day = "16",
doi = "10.1126/scitranslmed.aag2374",
language = "English (US)",
volume = "8",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "365",

}

TY - JOUR

T1 - Oral, ultra-long-lasting drug delivery

T2 - Application toward malaria elimination goals

AU - Bellinger, Andrew M.

AU - Jafari, Mousa

AU - Grant, Tyler M.

AU - Zhang, Shiyi

AU - Slater, Hannah C.

AU - Wenger, Edward A.

AU - Mo, Stacy

AU - Lee, Young Ah Lucy

AU - Mazdiyasni, Hormoz

AU - Kogan, Lawrence

AU - Barman, Ross

AU - Cleveland, Cody

AU - Booth, Lucas

AU - Bensel, Taylor

AU - Minahan, Daniel

AU - Hurowitz, Haley M.

AU - Tai, Tammy

AU - Daily, Johanna P.

AU - Nikolic, Boris

AU - Wood, Lowell

AU - Eckhoff, Philip A.

AU - Langer, Robert

AU - Traverso, Giovanni

PY - 2016/11/16

Y1 - 2016/11/16

N2 - Efforts at elimination of scourges, such as malaria, are limited by the logistic challenges of reaching large rural populations and ensuring patient adherence to adequate pharmacologic treatment. We have developed an oral, ultra-long-acting capsule that dissolves in the stomach and deploys a star-shaped dosage form that releases drug while assuming a geometry that prevents passage through the pylorus yet allows passage of food, enabling prolonged gastric residence. This gastric-resident, drug delivery dosage form releases small-molecule drugs for days to weeks and potentially longer. Upon dissolution of the macrostructure, the components can safely pass through the gastrointestinal tract. Clinical, radiographic, and endoscopic evaluation of a swine largeanimal model that received these dosage forms showed no evidence of gastrointestinal obstruction or mucosal injury. We generated long-acting formulations for controlled release of ivermectin, a drug that targets malariatransmitting mosquitoes, in the gastric environment and incorporated these into our dosage form, which then delivered a sustained therapeutic dose of ivermectin for up to 14 days in our swine model. Further, by using mathematical models of malaria transmission that incorporate the lethal effect of ivermectin against malariatransmitting mosquitoes, we demonstrated that this system will boost the efficacy of mass drug administration toward malaria elimination goals. Encapsulated, gastric-resident dosage forms for ultra-long-acting drug delivery have the potential to revolutionize treatment options for malaria and other diseases that affect large populations around the globe for which treatment adherence is essential for efficacy.

AB - Efforts at elimination of scourges, such as malaria, are limited by the logistic challenges of reaching large rural populations and ensuring patient adherence to adequate pharmacologic treatment. We have developed an oral, ultra-long-acting capsule that dissolves in the stomach and deploys a star-shaped dosage form that releases drug while assuming a geometry that prevents passage through the pylorus yet allows passage of food, enabling prolonged gastric residence. This gastric-resident, drug delivery dosage form releases small-molecule drugs for days to weeks and potentially longer. Upon dissolution of the macrostructure, the components can safely pass through the gastrointestinal tract. Clinical, radiographic, and endoscopic evaluation of a swine largeanimal model that received these dosage forms showed no evidence of gastrointestinal obstruction or mucosal injury. We generated long-acting formulations for controlled release of ivermectin, a drug that targets malariatransmitting mosquitoes, in the gastric environment and incorporated these into our dosage form, which then delivered a sustained therapeutic dose of ivermectin for up to 14 days in our swine model. Further, by using mathematical models of malaria transmission that incorporate the lethal effect of ivermectin against malariatransmitting mosquitoes, we demonstrated that this system will boost the efficacy of mass drug administration toward malaria elimination goals. Encapsulated, gastric-resident dosage forms for ultra-long-acting drug delivery have the potential to revolutionize treatment options for malaria and other diseases that affect large populations around the globe for which treatment adherence is essential for efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84995608772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995608772&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aag2374

DO - 10.1126/scitranslmed.aag2374

M3 - Article

C2 - 27856796

AN - SCOPUS:84995608772

VL - 8

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 365

ER -